52w high/low | ₹1.9 / ₹0 |
P/E ratio | -1.37 |
Dividend | 0 |
Face value | 10 |
Book value | ₹-5.97Cr |
Market capital | ₹11.22Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Jointly promoted by J K Industries and TIDCO, J K Pharmachem manufactures drugs and pharmaceuticals. It entered the capital market in Oct. '94 to part-finance the setting up of a plant to manufacture 1250 MMU P. a of pencillin-G, based on a microbial strain from the technical collaborators -- IGC (Cyprus), Cyprus -- a wholly-owned subsidiary of ICN Galenika. Commercial production at this plant commenced in Oct. '95. The company has a tie-up with ICN Galenika, part of the ICN Pharmaceuticals group (one of the pioneering manufacturers of pencillin-G), to set up a 1250-mmu capacity plant. It has already produced international standard penicillin with Indian raw materials, at its collaborator's plant which is among the best in the world.